
Home » FDA Clears Erchonia’s Low Level Laser for Treating Musculoskeletal Pain
FDA Clears Erchonia’s Low Level Laser for Treating Musculoskeletal Pain

July 17, 2019
The FDA has granted Erchonia 510(k) clearance for its FX-635 laser system for the temporary treatment of musculoskeletal pain caused by physical injury.
The system uses controlled, low-level laser technology and diode arms to precisely target areas of pain in the patient’s lower back. It eliminates the need for opioids and nonsteroidal anti-inflammatory drugs. The system is non-invasiveness and has a shorter recuperation period.
Double-blind and placebo-controlled clinical trials showed a 49 percent average pain reduction after treatment without any other therapies.
Upcoming Events
-
21Apr
-
26Apr
-
06May
-
12May
-
25May